Goldman Sachs is out with a research note this morning, where it suggests that traders buy calls on Vertex Pharmaceuticals Incorporated VRTX ahead of three key drug catalysts.
Goldman Sachs SMid Cap Biotechnology Analyst, Terence Flynn, expects three upcoming catalysts to be positive for Buy-rated VRTX.
1. This week: Approval of Merck's Boceprevir (and pricing decision) should be stock moving for VRTX.
2. This month: “Significant” upside potential to shares from CF combo data; market opportunity could be double vs low expectations.
3. May 23: TVR approval date – Broader label, higher pricing, expecting positive catalyst for shares.
Following the upcoming May 23 approval date for VRTX's key drug, TVR, he believes VRTX may become a more attractive M&A value of $87.
Goldman suggests buying the July $55 calls for $5.70.
Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing and commercializing small molecule drugs for the treatment of diseases.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in